
[Federal Register Volume 76, Number 162 (Monday, August 22, 2011)]
[Notices]
[Page 52334]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 2011-21380]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

[Docket No. FDA-2011-N-0002]


Arthritis Advisory Committee; Notice of Postponement of Meeting

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.

-----------------------------------------------------------------------

SUMMARY: The Food and Drug Administration (FDA) is postponing the 
Arthritis Advisory Committee meeting scheduled for September 13, 2011. 
This meeting was announced in the Federal Register of July 19, 2011 (76 
FR 42715). The postponement is due to the fact that the Agency recently 
received submissions from some of the investigational new drug (IND) 
application holders for anti-nerve growth factor (Anti-NGF) antibody 
drug products that contain large quantities of new information that 
will require additional time for Agency review prior to the advisory 
committee meeting.

FOR FURTHER INFORMATION CONTACT: Philip A. Bautista, Center for Drug 
Evaluation and Research, Food and Drug Administration, 10903 New 
Hampshire Ave., Bldg. 31, rm. 2417, Silver Spring, MD 20993-0002, 301-
796-9001, FAX 301-827-8533, e-mail: AAC@fda.hhs.gov, or FDA Advisory 
Committee Information Line, 1-800-741-8138 (301-443-0572 in the 
Washington, DC area), and follow the prompts to the desired center or 
product area. Please call the Information Line for up-to-date 
information on this meeting.

    Dated: August 17, 2011.
Leslie Kux,
Acting Assistant Commissioner for Policy.
[FR Doc. 2011-21380 Filed 8-19-11; 8:45 am]
BILLING CODE 4160-01-P


